PT Journal
AU Reijs, BLR
   Teunissen, CE
   Goncharenko, N
   Betsou, F
   Blennow, K
   Baldeiras, I
   Brosseron, F
   Cavedo, E
   Fladby, T
   Froelich, L
   Gabryelewicz, T
   Gurvit, H
   Kapaki, E
   Koson, P
   Kulic, L
   Lehmann, S
   Lewczuk, P
   Lleó, A
   Mätzler, W
   de Mendonça, A
   Miller, A
   Molinuevo, JL
   Mollenhauer, B
   Parnetti, L
   Rot, U
   Schneider, A
   Simonsen, AH
   Tagliavini, F
   Tsolaki, M
   Verbeek, MM
   Verhey, FRJ
   Zboch, M
   Winblad, B
   Scheltens, P
   Zetterberg, H
   Visser, PJ
TI The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases
SO Frontiers in Neurology
PY 2015
BP S. 216:1 - 216:7
VL 6
PU Frontiers Media SA
DI 10.3389/fneur.2015.00216
WP https://macau.uni-kiel.de/receive/publ_mods_00002353
LA en
DE Alzheimer's disease; Parkinson's disease; biobank; body fluids; cerebrospinal fluid; dementia; neurodegenerative disorders
SN 1664-2295
AB Biobanks are important resources for biomarker discovery and assay development. Biomarkers for Alzheimer's and Parkinson's disease (BIOMARKAPD) is a European multicenter study, funded by the EU Joint Programme-Neurodegenerative Disease Research, which aims to improve the clinical use of body fluid markers for the diagnosis and prognosis of Alzheimer's disease (AD) and Parkinson's disease (PD). The objective was to standardize the assessment of existing assays and to validate novel fluid biomarkers for AD and PD. To support the validation of novel biomarkers and assays, a central and a virtual biobank for body fluids and associated data from subjects with neurodegenerative diseases have been established. In the central biobank, cerebrospinal fluid (CSF) and blood samples were collected according to the BIOMARKAPD standardized pre-analytical procedures and stored at Integrated BioBank of Luxembourg. The virtual biobank provides an overview of available CSF, plasma, serum, and DNA samples at each site. Currently, at the central biobank of BIOMARKAPD samples are available from over 400 subjects with normal cognition, mild cognitive impairment (MCI), AD, frontotemporal dementia (FTD), vascular dementia, multiple system atrophy, progressive supranuclear palsy, PD, PD with dementia, and dementia with Lewy bodies. The virtual biobank contains information on over 8,600 subjects with varying diagnoses from 21 local biobanks. A website has been launched to enable sample requests from the central biobank and virtual biobank.
PI Lausanne
ER